Anthem leaves Express Scripts behind to roll out its own PBM

Named IngenioRx, the new pharma middleman is scheduled to debut in 2020.

By Jacob Bell • Oct. 18, 2017

CVS aims to cut patient drug costs through EHR collaboration

The PBM will work with electronic health records provider Epic to give prescribers better visibility into lower cost options. 

By Suzanne Elvidge • Oct. 18, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Trevena cuts workforce 30% to free up cash

In a "re-positioning" effort, the company is focusing more resources on getting its pain med Olinvo approved and commercialized.

By Jacob Bell • Oct. 13, 2017

Merck's StayWell nabs mobile app maker MedHelp

The deal helps to strengthen Merck’s role in diabetes management.

By Meg Bryant • Oct. 12, 2017

Long rundowns of side effects can make drugs seem less risky, study finds

Paradoxically, exhaustively listing risks in DTC ads can dilute consumer perception of the severity of a drug's side effects, according to new research.

By Ned Pagliarulo • Oct. 11, 2017

Lupin expands US presence with $150M Symbiomix deal

While branded drugs remain a small contributor to Lupin's overall sales, the Indian generics maker hopes acquiring Symbiomix will help build its specialty business.

By Ned Pagliarulo • Oct. 11, 2017

Clovis looks to expand label for PARP inhibitor

Securing approval to expand use of Rubraca for a broader group of patients will be a key step if Clovis is to catch up with its PARP rivals.

By Suzanne Elvidge • Oct. 11, 2017

Insys calls opioid allegations 'unfair'

After several states brought lawsuits against the company, Insys responded by noting the steps it has taken to fix past mistakes.

By Lisa LaMotta • Oct. 9, 2017

Flexion secures US approval for osteoarthritis drug

The biotech is highlighting the drug as a non-opioid, non-surgical option for knee pain associated with the chronic condition. 

By Ned Pagliarulo • Oct. 9, 2017

Report: Amazon near a decision about pharmacy sales

As the e-commerce giant weighs whether to jump into the volatile space, shares of drug store retailers Walgreens, CVS Health and Rite Aid all fell on Friday.

By Daphne Howland • Oct. 9, 2017

PCSK9 court saga drags on for Sanofi, Regeneron and Amgen

A court has allowed for the continued sale of Praluent, while the companies continue to battle it out over the flailing market. 

By Suzanne Elvidge • Oct. 6, 2017

Insys hit with lawsuit, fine for opioid marketing

The latest litigation against Insys comes from the state of New Jersey, which is accusing the company of "titanic greed and corporate irresponsibility."

By Lisa LaMotta • Oct. 5, 2017

Motif delivers more strong data on its antibiotic

In another late-stage study, the company's iclaprim demonstrated non-inferiority to standard-of-care in treating bacterial skin infections. 

By Jacob Bell • Oct. 5, 2017

CVS to use prescription labeling from Target designer

Despite accolades and the popularity of designer Deborah Adler's Target Pharmacy labeling, CVS didn't adopt it when it took over Target's pharmacy business — until now.

By Daphne Howland • Oct. 5, 2017

Allergan to Congress: The IPR system needs fixing

In a recently penned letter, CEO Brent Saunders defended his company's decision to protect Restasis patents by working with the Saint Regis Mohawk Tribe.

By Jacob Bell • Oct. 4, 2017

Generic makers fail to stop drug pricing law

The Association for Accessible Medicines' lawsuit has failed to halt Maryland's House Bill 631 going into effect this weekend.

By Suzanne Elvidge • Oct. 4, 2017

Express Scripts: Specialty meds driving up US drug spend

A new report from the PBM found the number of health plan members whose annual pharmacy bill cost more than $50,000 had spiked by 35% since 2014. 

By Ned Pagliarulo • Oct. 2, 2017

Ablynx prepares path for lead drug after positive late-stage results

Caplacizumab met primary and key secondary goals of the HERCULES study, which evaluated the drug in patients with a rare blood disorder.

By Jacob Bell • Oct. 2, 2017

Lilly's abema gets FDA OK, setting it up for blockbuster status

Verzenio comes as the third CDK 4/6 inhibitor to market, facing competition from Pfizer's Ibrance and Novartis' Kisqali, but it could be best in class.

By Jacob Bell • Sept. 29, 2017

AbbVie, Amgen reach a deal on Humira biosimilar

Now, a copycat of the mega-blockbuster anti-inflammatory drug likely won't reach the U.S. market until 2023.

By Jacob Bell • Sept. 28, 2017

Coverage barriers and high co-pays block access to PCSK9 drugs

Only a third of patients prescribed Repatha or Praluent in the drugs' first year of availability actually ended up receiving therapy, according to a new study. 

By Suzanne Elvidge • Sept. 28, 2017

FDA targets illegal online pharmacies as part of global crackdown

In a recent enforcement effort, the U.S. regulator sent 13 warning letters to the operators of 401 websites peddling illegal or counterfeit medicines. 

By Suzanne Elvidge • Sept. 27, 2017

AbbVie to keep limits on price hikes next year, denying backtrack

Pressure ratcheted up on AbbVie after reports suggested the drugmaker was considering returning to double-digit price increases in 2018.

By Ned Pagliarulo • Sept. 27, 2017

J&J, Roche among companies selected for FDA digital health pilot

The regulator hopes to improve how it reviews digital medical devices, aiming to streamline the path to market for new health tools.

By Jeff Byers • Sept. 26, 2017

What you need to know: The evolving pharma sales force

BioPharma Dive's latest Spotlight examines how the pressures of shifting markets, patent expirations and industry restructurings have impacted sales forces. 

By Lisa LaMotta • Sept. 26, 2017